Cargando…

Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent (177)Lu-DOTATOC therapy

BACKGROUND: Patients with advanced neuroendocrine tumors (NETs) of the midgut are suitable candidates for (177)Lu-DOTATOC therapy. Integrated SPECT/CT systems have the potential to help improve the accuracy of patient-specific tumor dosimetry. Dose estimations to target organs are generally performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goetz, Th. I., Lang, E. W., Prante, O., Maier, A., Cordes, M., Kuwert, T., Ritt, P., Schmidkonz, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101301/ https://www.ncbi.nlm.nih.gov/pubmed/32114682 http://dx.doi.org/10.1007/s12149-020-01440-3

Ejemplares similares

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study
por: Prasad, Vikas, et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC
por: Gühne, Falk, et al.
Publicado: (2021)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy
por: Ardenfors, Oscar, et al.
Publicado: (2022)

Accuracy of two dosimetry software programs for (177)Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
por: Ramonaheng, Keamogetswe, et al.
Publicado: (2022)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

Tumor dosimetry using (177)Lu: influence of background activity, measurement method and reconstruction algorithm
por: Staanum, Peter Frøhlich
Publicado: (2023)

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points
por: Chen, Gefei, et al.
Publicado: (2023)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2022)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

Evaluation of Dosimetric Parameters for Tumor Therapy with (177)Lu and (90)Y Radionuclides in Gate Monte Carlo Code
por: Peer-Firozjaei, Milad, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy
por: Marin, Gwennaëlle, et al.
Publicado: (2017)

Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)

Radiation exposure assessment of nuclear medicine staff administering [(177)Lu]Lu-DOTA-TATE with active and passive dosimetry
por: Riveira-Martin, Mercedes, et al.
Publicado: (2023)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Brachytherapy Approach Using (177)Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model
por: Lin, Min-Ying, et al.
Publicado: (2021)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Towards accurate (177)Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio
por: Raskin, Stanislav, et al.
Publicado: (2023)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections
por: de Nijs, Robin, et al.
Publicado: (2014)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy
por: Brosch-Lenz, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nbv18mv9rdhomhtm21m1o4ufh9